Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

Rhea-AI Summary

Fortress Biotech (Nasdaq: FBIO) reported third-quarter 2026 revenue of $19.2 million, up approximately 9% from the prior-year quarter. Common stockholders recorded a $7.9 million loss, or $0.23 per basic and diluted share, versus $3.7 million income a year earlier. Consolidated cash reached $152.2 million at September 30, versus $79.4 million at December 31, 2025.

Fortress repaid the remaining $15.0 million Oaktree principal in September, leaving no parent-level debt. A controlled subsidiary licensed FB-607 from Cedars-Sinai for diarrhea-predominant irritable bowel syndrome; Fortress expects Phase 2 top-line data in the second half of 2027. Anselamimab received Japanese approval, while ZYCUBO and UNLOXCYT generated royalties. Nine-month common-stockholder income reached $98.036 million versus $4.316 million, with a $158.873 million net gain on a priority review voucher sale.

19 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 11 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointPriority review voucher sale generated a $158.873 million gain, net of expenses, in the first nine months of 2026. 2.4× market cap
• Moderate pointThird-quarter revenue rose approximately 9% year over year to $19.2 million.
• Moderate pointConsolidated cash increased to $152.2 million at September 30, 2026, from $79.4 million at year-end 2025.
• Moderate point$15.0 million Oaktree principal repayment eliminated parent-level debt and released the facility’s liens in September 2026. 23% of market cap
• Moderate pointNine-month revenue increased to $53.914 million from $47.183 million a year earlier.
• Moderate pointNine-month operating loss narrowed to $24.937 million from $65.432 million a year earlier.
• Moderate pointControlled subsidiary’s exclusive FB-607 license adds a Phase 2 program from Cedars-Sinai for diarrhea-predominant irritable bowel syndrome.
• Moderate pointTotal liabilities declined to $103.194 million at September 30, 2026, from $123.365 million at year-end 2025.

11 minor points

• Minor pointNine-month common-stockholder income rose to $98.036 million from $4.316 million; diluted EPS rose to $2.51 from $0.14.
• Minor point. Forward-looking: it has not happened yet and may not happen.FB-607 Phase 2 top-line data are expected by Fortress in the second half of 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.Anselamimab’s Japanese approval advances a program carrying Fortress sales-based milestone eligibility; an FDA-approval milestone remains conditional.
• Minor pointDotinurad development continues through two Phase 3 trials and a Phase 2 study; Urica holds equity and future royalty eligibility.
• Minor point. Forward-looking: it has not happened yet and may not happen.Urica’s dotinurad royalty eligibility is 3% of future net sales.
• Minor pointThird-quarter royalty revenue included $0.2 million for Cyprium from ZYCUBO and $0.1 million contingent-consideration income for Fortress from UNLOXCYT.
• Minor pointTriplex development continues in transplant-related cytomegalovirus trials and combination trials with CAR T-cell therapies.
• Minor point. Forward-looking: it has not happened yet and may not happen.MB-109 trial initiation in first-quarter 2027 is being explored for specified recurrent brain cancers.
• Minor pointThird-quarter interest income increased to $1.295 million from $0.736 million a year earlier.
• Minor pointThird-quarter interest expense and financing fees decreased to $2.498 million from $2.742 million a year earlier.
• Minor pointThird-quarter acquired-intangible amortization decreased to $0.969 million from $1.064 million a year earlier.

Negative

• Moderate pointThird-quarter common-stockholder loss was $7.853 million versus $3.675 million income; diluted EPS fell to negative $0.23 from $0.11.
• Moderate pointNine-month partner-company derivative liability remeasurement produced a $7.085 million expense versus none a year earlier. 11% of market cap
• Minor pointThird-quarter operating loss widened to $7.193 million from $6.811 million a year earlier.
• Minor pointThird-quarter research and development expense increased to $1.678 million from $0.208 million a year earlier.
• Minor pointThird-quarter selling, general and administrative expense increased to $17.821 million from $17.415 million a year earlier.

6 minor points

• Minor pointThird-quarter cost of goods, excluding acquired-intangible amortization, increased to $5.884 million from $5.755 million a year earlier.
• Minor pointThird-quarter other revenue declined to $0.234 million from $0.606 million a year earlier.
• Minor pointThird-quarter other income and expense shifted to $0.018 million expense from $17.672 million income a year earlier.
• Minor pointOutstanding common shares increased to 33,490,362 at September 30, 2026, from 31,364,094 at year-end 2025.
• Minor pointConsolidated debt remained: $18.077 million long-term notes payable, net, and $7.500 million short-term partner-company notes at September 30.
• Minor pointNine-month income tax expense increased to $5.395 million from $0.196 million a year earlier.

News Explained

The Oaktree payoff ended parent borrowing, not all consolidated notes payable.

The September Oaktree repayment was complete; common shares issued and outstanding totaled 33,490,362 at September 30, 2026.

The repayment ended the parent-level Oaktree borrowing, but the consolidated balance sheet still listed $7,500 thousand in short-term partner-company notes payable and $18,077 thousand in long-term notes payable, net, as of September 30, 2026.

Key Figures

Net revenue: $19.2 million Net loss attributable to common stockholders: $(7.9) million EPS: $(0.23) per share +4 more

Net revenue

$19.2 million

Q3 2026; approximately 9% higher year over year

Net loss attributable to common stockholders

$(7.9) million

Q3 2026; compared with net income of $3.7 million in Q3 2025

EPS

$(0.23) per share

Q3 2026, basic and diluted

Consolidated cash and cash equivalents

$152.2 million

As of September 30, 2026

Oaktree principal repaid

$15.0 million

Remaining principal repaid in full in September 2026

FB-607 top-line data

Second half of 2027

Expected timing; Phase 2 IBS-D study

Emrosi prescriptions

Approximately 40,000 prescriptions

Q3 2026

Previous Earnings Reports

1 past event · Latest: Aug 13

Same Type 1 event

1. Aug 13

   Quarterly earnings

   24h Move

   -1.7%

   Revenue rose, but common-stockholders recorded a loss versus prior-year income; shares fell 1.68%.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

randomized, double-blind, placebo-controlled, phase 2 study

4 terms

randomized medical

"randomized, double-blind, placebo-controlled, Phase 2 study"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

double-blind medical

"randomized, double-blind, placebo-controlled, Phase 2 study"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"randomized, double-blind, placebo-controlled, Phase 2 study"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

phase 2 study medical

"currently being evaluated in a multi-center, randomized, double-blind, placebo-controlled Phase 2 study"

A phase 2 study is a mid-stage clinical trial that tests whether an experimental drug or treatment actually works for the intended condition and continues to check safety in a larger group of patients than early trials. Think of it as a focused pilot test before a full market launch; positive or negative results strongly affect a drug’s chances of approval, the remaining development time and costs, and therefore an investment’s risk and potential value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025

Fortress repaid its credit facility in full in September 2026

A subsidiary of Fortress entered into a license agreement for FB-607, which is currently being evaluated in a randomized, double-blind, placebo-controlled Phase 2 study to assess the safety and efficacy in patients with irritable bowel syndrome with diarrhea

Partnered programs continue to advance, with Crystalys Therapeutics closing a $130 million Series B financing, and royalties generated from ZYCUBO^® and UNLOXCYT™

MIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2026.

Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “The third quarter of 2026 reflected continued execution across our diversified portfolio. In September, we repaid in full our credit facility with Oaktree and we also recently announced the in-licensing of FB-607, a novel combination therapy to treat the symptoms of irritable bowel syndrome with diarrhea (“IBS-D”). FB-607 is currently being studied in a randomized, placebo-controlled, Phase 2 trial for IBS-D and we expect to release top-line data in the second half of 2027. Journey Medical continues to build momentum with Emrosi^®, with approximately 40,000 in total prescriptions for the third quarter of 2026, supported by continued improvement in the mix of prescriptions reimbursed by health plans. Additionally, in September, anselamimab (formerly CAEL-101) was approved in Japan for the treatment of systemic kappa light chain amyloidosis. With our growing royalty income from ZYCUBO^® and UNLOXCYT™, and multiple potential catalysts across our partnered programs, we believe Fortress is well positioned to continue driving long-term value for our shareholders.”

Recent Corporate Highlights¹:

Corporate Updates

• Fortress Repays Oaktree Credit Facility in Full. In September 2026, Fortress repaid in full the remaining $15.0 million in outstanding principal under its senior secured credit agreement with Oaktree Fund Administration, LLC (the “Oaktree Agreement”). Upon repayment, all indebtedness under the Oaktree Agreement was satisfied and paid in full, all liens and other security interests in Fortress’ property securing the facility were released and terminated, and the Oaktree Agreement terminated in accordance with its terms. Fortress originally entered into the $50.0 million credit facility in July 2024. Following the repayment, Fortress has no outstanding debt at the parent level.
• Fortress Subsidiary Licenses FB-607 for IBS-D. In the third quarter of 2026, a majority-owned and controlled private subsidiary of Fortress entered into an exclusive licensing agreement with Cedars-Sinai to develop FB-607, a novel drug with the potential to improve care for patients with IBS-D. FB-607 is currently being evaluated in a multi-center, randomized, double-blind, placebo-controlled Phase 2 study to assess the safety and efficacy in patients with IBS-D.

Commercial Portfolio Updates

• Journey Medical Continues to Grow Emrosi^®. At the end of March 2025, our partner company Journey Medical Corporation (“Journey Medical”) commercially launched Emrosi^® (40mg Minocycline Hydrochloride Modified-Release Capsules, consisting of 10mg immediate release and 30mg extended release pellets), also known as DFD-29, for inflammatory lesions of rosacea. Emrosi^® was approved by the FDA in November 2024 and is available by prescription at specialty pharmacy chains. Journey Medical reported that Emrosi^® had generated approximately 40,000 prescriptions in the third quarter of 2026. Journey Medical reported net product revenues of $18.9 million for the third quarter of 2026, compared to net product revenues of $17.0 million for the third quarter ended September 30, 2025.
• Royalties. In the third quarter of 2026, Cyprium Therapeutics, Inc. (“Cyprium”) recognized $0.2 million in royalty revenue on net sales of ZYCUBO^®, and Fortress recognized $0.1 million in royalty income (contingent consideration) on net sales of UNLOXCYT™.

Clinical Updates

• Crystalys Raises $130M Series B. In July 2026, Crystalys Therapeutics (“Crystalys”) announced a $130 million Series B financing to support the late-stage global clinical development and commercialization preparation for dotinurad. Patients continue to be enrolled in Crystalys’ two randomized, double-blind, multicenter global Phase 3 trials, RUBY and TOPAZ, evaluating dotinurad, a next-generation, once daily oral URAT1 inhibitor with potential for best-in-class safety and efficacy for the treatment of gout, as well as its Phase 2 AMETHYST study in difficult-to-treat gout. Our controlled subsidiary Urica is an equity holder of Crystalys and eligible to receive a 3% royalty on future net sales of dotinurad.
• Anselamimab Receives Approval in Japan. In September 2026, anselamimab (formerly known as CAEL-101) was approved in Japan for the treatment of systemic kappa light chain amyloidosis. Through the sale of Caelum Biosciences, Fortress is eligible to receive commercial milestone payments based on sales and a regulatory milestone payment upon approval by the FDA.
• Other Portfolio Programs Continue to Advance with Potential Upcoming Data and Trial Initiations. Triplex is currently in multiple ongoing clinical trials for cytomegalovirus (CMV) treatment and prevention in solid organ and stem cell transplants, combination trials with CAR T cell therapies for hematologic malignancies. We are exploring the possibility of initiating a clinical trial evaluating MB-109, a combination CAR T cell therapy and oncolytic virus, in the first quarter of 2027 for patients with IL13Rα2-positive recurrent glioblastoma and high-grade astrocytoma.
  

Financial Results:

• As of September 30, 2026, Fortress’ consolidated cash and cash equivalents totaled $152.2 million, compared to $79.4 million as of December 31, 2025, an increase of $72.8 million year-to-date.
• Fortress’ consolidated cash and cash equivalents totaling $152.2 million as of September 30, 2026 includes $114.1 million attributable to Fortress and the private subsidiaries, $1.5 million attributable to Avenue Therapeutics, $14.3 million attributable to Mustang Bio and $22.3 million attributable to Journey Medical.
  • Fortress’ consolidated cash and cash equivalents totaled $79.4 million as of December 31, 2025, and includes $35.2 million attributable to Fortress and private subsidiaries, $2.9 million attributable to Avenue Therapeutics, $17.3 million attributable to Mustang Bio and $24.1 million attributable to Journey Medical.
• Fortress’ consolidated net revenue totaled $19.2 million for the third quarter ended September 30, 2026, $18.9 million of which was generated from our marketed dermatology products. This compares to consolidated net revenue totaling $17.6 million for the third quarter of 2025, $17.0 million of which was generated from our marketed dermatology products.
• Consolidated research and development expenses totaled $1.7 million for the third quarter ended September 30, 2026, compared to $0.2 million for the third quarter ended September 30, 2025.
• Consolidated selling, general and administrative costs were $17.8 million for the third quarter ended September 30, 2026, compared to $17.4 million for the third quarter ended September 30, 2025.
• Consolidated net loss attributable to common stockholders was $(7.9) million, or $(0.23) per share basic and diluted, for the third quarter ended September 30, 2026, compared to net income attributable to common stockholders of $3.7 million, or $0.13 per share basic, and $0.11 per share diluted, for the third quarter ended September 30, 2025.
  

About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Institute and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements
Statements in this press release that are not descriptions of historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology are generally intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include risks relating to: our growth strategy, financing and strategic agreements and relationships; our need for substantial additional funds and uncertainties relating to financings; uncertainty related to the timing and amounts expected to be realized from future milestone, contingent value right, royalty or similar future revenue streams, if at all; our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; our ability to attract, integrate and retain key personnel; the early stage of product candidates under development; the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain regulatory approval for products under development; our ability to successfully commercialize products for which we receive regulatory approval or receive royalties or other distributions from third parties; our ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companies’ products and product candidates; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com

FORTRESS BIOTECH, INC. AND SUBSIDIARIES Unaudited Condensed Consolidated Balance Sheets ($ in thousands except for share and per share amounts)
	September 30, 2026				December 31, 2025
ASSETS
Current assets
Cash and cash equivalents	$	152,186			$	79,381
Accounts receivable, net		47,387				29,783
Inventory		7,772				9,624
Other receivables - related party		54				158
Prepaid expenses and other current assets		2,964				4,895
Total current assets		210,363				123,841
Property and equipment, net		2,320				2,519
Operating lease right-of-use asset, net		11,028				12,302
Restricted cash		1,220				1,220
Equity investments, at fair value		29,452				17,660
Intangible assets, net		24,541				27,605
Other assets		1,291				401
Total assets	$	280,215			$	185,548
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued expenses	$	56,628			$	47,125
Income taxes payable		5,119				356
Common stock warrant liabilities		—				1
Operating lease liabilities, short-term		2,513				2,127
Partner company notes payable, short-term		7,500				—
Other current liabilities		—				135
Total current liabilities		71,760				49,744
Notes payable, long-term, net		18,077				52,417
Operating lease liabilities, long-term		10,861				12,672
Partner company redeemable perpetual preferred liability		—				7,085
Other long-term liabilities		2,496				1,447
Total liabilities		103,194				123,365
Commitments and contingencies
Stockholders’ equity
Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively, liquidation value of $25.00 per share		3				3
Common stock, $0.001 par value, 200,000,000 shares authorized, 33,490,362 and 31,364,094 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively		33				31
Additional paid-in-capital		789,953				783,891
Accumulated deficit		(629,992	)			(734,052	)
Total stockholders' equity attributed to the Company		159,997				49,873
Non-controlling interests		17,024				12,310
Total stockholders' equity		177,021				62,183
Total liabilities and stockholders' equity	$	280,215			$	185,548

FORTRESS BIOTECH, INC. AND SUBSIDIARIES Unaudited CondensedConsolidated Statements of Operations ($ in thousands except for share and per share amounts)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Revenue
Product revenue, net	$	18,925			$	17,025			$	52,685			$	45,173
Other revenue		234				606				1,229				2,010
Net revenue		19,159				17,631				53,914				47,183
Operating expenses
Cost of goods - (excluding amortization of acquired intangible assets)		5,884				5,755				18,245				15,484
Amortization of acquired intangible assets		969				1,064				3,064				3,193
Research and development		1,678				208				3,023				12,268
Selling, general and administrative		17,821				17,415				54,519				81,670
Total operating expenses		26,352				24,442				78,851				112,615
Loss from operations		(7,193	)			(6,811	)			(24,937	)			(65,432	)
Other income (expense)
Interest income		1,295				736				3,446				1,848
Interest expense and financing fee		(2,498	)			(2,742	)			(7,342	)			(8,065	)
Gain on sale of priority review voucher, net of expenses		—				—				158,873				—
Change in fair value of partner company derivative liability		—				—				(7,085	)			—
Loss on common stock warrant liabilities		—				(2	)			1				(399	)
Gain from deconsolidation of subsidiary		104				—				186				27,127
Other income (expense)		(18	)			17,672				11,764				17,599
Total other income (expense)		(1,117	)			15,664				159,843				38,110
Income (loss) before income tax expense		(8,310	)			8,853				134,906				(27,322	)
Income tax (benefit) expense		(56	)			26				5,395				196
Net income (loss)		(8,254	)			8,827				129,511				(27,518	)
Attributable to non-controlling interests		2,409				(2,977	)			(25,451	)			38,270
Net income (loss) attributable to Fortress	$	(5,845	)		$	5,850			$	104,060			$	10,752
Preferred A dividends cumulated, and Fortress' share of subsidiary deemed dividends		(2,008	)			(2,174	)			(6,024	)			(6,436	)
Net income (loss) attributable to common stockholders	$	(7,853	)		$	3,675			$	98,036			$	4,316
Net income (loss) per common share attributable to common stockholders - basic	$	(0.23	)		$	0.13			$	2.94			$	0.16
Net income (loss) per common share attributable to common stockholders - diluted	$	(0.23	)		$	0.11			$	2.51			$	0.14
Weighted average common shares outstanding - basic		33,746,832				27,244,474				33,394,537				27,075,216
Weighted average common shares outstanding - diluted		33,746,832				33,100,961				38,997,513				30,695,996

                              

¹ This press release references products being developed or commercialized by Fortress, by Fortress’ private or public subsidiaries (referred to herein as “subsidiaries” or “partner companies”) and by entities with whom one of the foregoing parties has a significant business relationship, such as an exclusive license or an ongoing product-related payment obligation (such entities referred to herein as “partners”). The words “we”, “us” and “our” may refer to Fortress individually, to one or more of our subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Fortress Biotech’s third-quarter 2026 revenue and earnings?

Fortress reported $19.2 million revenue and a $7.9 million common-stockholder loss, or $0.23 per basic and diluted share. The prior-year quarter had $17.6 million revenue and $3.7 million common-stockholder income, or $0.13 per basic share and $0.11 per diluted share.

When does Fortress Biotech expect FB-607 Phase 2 results?

Fortress expects top-line Phase 2 data in the second half of 2027. FB-607 is being evaluated in a multicenter, randomized, double-blind, placebo-controlled study assessing safety and efficacy in patients with irritable bowel syndrome with diarrhea.

How was Fortress Biotech’s September 2026 cash divided among its subsidiaries?

Of the $152.2 million consolidated cash and cash equivalents, $114.1 million was attributable to Fortress and private subsidiaries. Avenue Therapeutics accounted for $1.5 million, Mustang Bio for $14.3 million, and Journey Medical for $22.3 million.

How does Fortress Biotech participate in Crystalys’ dotinurad program?

Fortress’s controlled subsidiary Urica holds equity in Crystalys and is eligible for a 3% royalty on future dotinurad net sales. Crystalys closed a $130 million Series B financing to support late-stage global development and commercialization preparation. Enrollment continues in the Phase 3 RUBY and TOPAZ trials and Phase 2 AMETHYST study.

Which patients could enter Fortress Biotech’s proposed MB-109 trial?

Fortress is exploring a trial for patients with IL13Rα2-positive recurrent glioblastoma and high-grade astrocytoma. The potential first-quarter 2027 initiation would evaluate MB-109, a combination of CAR T-cell therapy and an oncolytic virus.